Nanoparticles contract manufacturing (focus on lipid and metal nanoparticles) market is anticipated to grow at a CAGR of over 8.5%, till 2035, claims Roots Analysis

Published: May 2022

The crucial role of nanoparticles as drug delivery systems has been extensively studied; these molecules also played a key role in the development of COVID-19 vaccines, enabling a surge in their demand and offering lucrative opportunities for contract manufacturers 

Roots Analysis has announced the addition of “Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market by Company Size, Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User, and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035” report to its list of offerings.

Many pharmaceutical players are actively trying to identify ways to improve / augment physiochemical properties and drug-like behavior of pharmacological products. Amidst other alternatives, the use of nanoparticles has garnered the attention of many drug developers. Players are also employing lipid / metal nanoparticles to re-formulate their existing products in order to further improve their bioavailability / biocompatibility.

To order this 195+ page report, which features 105+ figures and 110+ tables, please visit

Key Market Insights

Over 50 companies claim to offer nanoparticle contract manufacturing services
Presently, the market is dominated by the presence of small (2-50 employees) and mid-sized (51-200 employees) players, who represent over 65% of the contemporary market landscape. Additionally, it is worth noting that most of the service providers (over 55%) having the required capabilities for nanoparticles are based in North America.

Nearly 65% of the companies engaged in this industry provide services for metal nanoparticles
Of the aforementioned players, nearly half are contract manufacturing organizations (CMOs). Further, manufacturing facilities of around 40% such contract service providers are based in North America. Notably, around 50% of the total players engaged in this space offer their services to pharmaceutical companies.

Partnership activity in this field has increased at a CAGR of 43%, between 2015 and 2021
Around 55% of the reported deals were established in 2020 and 2021. Majority of the instances captured in the report (around 45%) were either product distribution agreements or instances of company acquisitions. Further, most of the instances captured in the report were inked with players based in Europe (nearly 55%).

Go / No-Go framework can be used to assist players in the crucial outsourcing decision-making process
The framework enables evaluation of the current capabilities of nanoparticle-based therapeutics developers, based on 4+ parameters, including trial phase, target therapeutic area, location of trial(s), patient enrollment and willingness to outsource.

The market is anticipated to grow at a CAGR of nearly 10%, during the period 2021-2035 
North America and Europe are expected to capture over 65% of the overall market share in 2035, in terms of sales-based revenues. Further, majority (~60%) of the market opportunity is anticipated to be associated with contract manufacturing services offered for metal nanoparticles.

To request a sample copy / brochure of this report, please visit this link

Key Questions Answered
  • Who are the key players offering contract manufacturing services for nanoparticles?
  • Which global regions are considered as key hubs for nanoparticle contract manufacturing?
  • What are the most common services offered by nanoparticle contract manufacturers?
  • What type of partnership models are commonly adopted by stakeholders engaged in this industry?
  • Which factors are likely to influence the make (in-house operations) versus buy (outsource operations) decision of nanoparticle developers?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the Nanoparticles Contract Manufacturing (Focus on Lipid and Metal Nanoparticles) Market has been analyzed across the following segments:

  • Company Size
  • Very Small
  • Small
  • Mid-Sized
  • Large
  • Type of Nanoparticle(s) Manufactured 
  • Lipid Nanoparticles
  • Metal Nanoparticles
  • Scale of Operation
  • Pre-Clinical
  • Clinical
  • Commercial
  • Type of End User 
  • Educational Institutions
  • Pharmaceutical Companies
  • Research Institutions
  • Other End Users
  • Key Geographical Regions 
  • North America
  • Europe
  • Asia 
  • Middle East and North Africa (MENA)
  • Latin America
  • Rest of the World 

The research covers detailed profiles of key players (listed below) engaged in this market; each profile features a brief company overview, along with information on recent developments of the firm, and an informed future outlook. 

  • Ardena
  • CordenPharma
  • Curia
  • Evonik
  • LSNE Contract Manufacturing
  • Polymun
  • TeachNanoIndia

For additional details, please email at

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry